Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Rifater 50 mg/300 mg/120 mg Tablets
Medicines register · Ireland

Rifater 50 mg/300 mg/120 mg Tablets

Authorisation PA0540/067/001 · Sanofi-Aventis Ireland Limited T/A SANOFI

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 19 Nov 2026
Licence holder
Sanofi-Aventis Ireland Limited T/A SANOFI (all products →)
Active substances
Isoniazid, Pyrazinamide, Rifampicin
Clinical trials
11 clinical trials → 10 clinical trials → 20 clinical trials →
Dosage form
Tablet
Route of administration
Oral use
ATC codes
J04AM, J04AM05
First authorised
09/02/1987
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Full application (Article 8(3) of Directive No 2001/83/EC)

Isoniazid: supply and approvals

3 authorised products on the HPRA list contain Isoniazid. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 18 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 18 Nov 2026)
Germany (BfArM)
2 supply notices, e.g. Isozid 0,5 N (8 Dec 2025 to 18 Dec 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

Pyrazinamide: supply and approvals

1 authorised product on the HPRA list contains Pyrazinamide. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 18 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 18 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 18 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

Rifampicin: supply and approvals

7 authorised products on the HPRA list contain Rifampicin. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 18 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 18 Nov 2026)
Germany (BfArM)
1 supply notice, e.g. EREMFAT 600 mg (19 Oct 2026 to 7 Dec 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 39 years (since 9 February 1987). The HPRA list marks it as marketed in Ireland.

Other medicines with Isoniazid in Ireland

2 other products on the HPRA list contain Isoniazid, from 1 licence holder; 2 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Rifinah 150/100 mg Film- Coated TabletsSanofi-Aventis Ireland Limited T/A SANOFINational authorisation (PA)Marketed
Rifinah 300/150 mg Film Coated TabletsSanofi-Aventis Ireland Limited T/A SANOFINational authorisation (PA)Marketed

Other medicines with Pyrazinamide in Ireland

No other product on the HPRA list contains Pyrazinamide.

The licence holder

Sanofi-Aventis Ireland Limited T/A SANOFI holds 54 products on the HPRA list, with 22 different active substances; 47 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 19 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.